Lista de obras - Sima Rafati - Dominio Público Uruguay

A Synthetic Peptide 2Abz23S29 Reduces Bacterial Titer and Induces Pro-Inflammatory Cytokines in a Murine Model of Urinary Tract Infection

artículo científico publicado en 2020

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers.

artículo científico publicado en 2013

A novel non-invasive diagnostic sampling technique for cutaneous leishmaniasis

artículo científico publicado en 2017

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

artículo científico publicado en 2001

Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis.

artículo científico publicado en 2006

Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials

artículo científico publicado en 2019

Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy

artículo científico publicado en 2016

Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites

artículo científico

Arginase activity of Leishmania isolated from patients with cutaneous leishmaniasis.

artículo científico publicado en 2017

Building Research and Development Capacity for Neglected Tropical Diseases Impacting Leishmaniasis in the Middle East and North Africa: A Case Study.

artículo científico publicado en 2015

C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice ⬇️

artículo científico publicado el 12 de julio de 2011

CD8(+) T cells in leishmania infections: friends or foes?

artículo científico publicado en 2012

Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.

artículo científico publicado en 2013

Chemokine-based immunotherapy: delivery systems and combination therapies.

artículo científico publicado en 2012

Comparing acute and chronic human cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica focusing on arginase activity

artículo científico publicado en 2016

Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice

artículo científico publicado en 2016

Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice

artículo científico publicado en 2006

Computational evaluation of modified peptides from human neutrophil peptide 1 (HNP-1)

artículo científico publicado en 2020

Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice

artículo científico publicado en 2009

Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection

article

Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice

artículo científico publicado en 2011

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals

artículo científico publicado en 2008

DNA Integration in Leishmania Genome: An Application for Vaccine Development and Drug Screening

artículo científico publicado en 2016

DNA plasmid coding for Phlebotomus sergenti salivary protein PsSP9, a member of the SP15 family of proteins, protects against Leishmania tropica

scientific article published on 11 January 2019

Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection

artículo científico publicado en 2011

Delivery systems for Leishmania vaccine development

artículo científico publicado en 2016

Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model

artículo científico publicado en 2012

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica.

artículo científico publicado en 2015

EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice.

artículo científico publicado en 2015

Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae

artículo científico publicado en 2011

Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies

artículo científico publicado en 2008

Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model

artículo científico publicado en 2016

Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen

artículo científico publicado en 2014

Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.

artículo científico publicado en 2014

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis

artículo científico publicado en 2010

Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice

artículo científico publicado en 2007

Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis

artículo científico publicado en 2003

Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies

artículo científico publicado en 2010

Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity

artículo científico publicado en 2015

Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice

artículo científico publicado en 2017

Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate

artículo científico publicado en 2013

Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population

artículo científico publicado en 2004

IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis

artículo científico publicado en 2015

Identification of Leishmania major cysteine proteinases as targets of the immune response in humans

artículo científico publicado en 2001

Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells.

artículo científico publicado en 2015

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

artículo científico publicado en 2003

Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies

artículo científico publicado en 2011

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

artículo científico publicado en 2004

Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7

article

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine

artículo científico publicado en 2014

Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice

article

Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.

artículo científico publicado en 2015

Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.

artículo científico publicado en 2012

Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen

artículo científico publicado en 2015

Improvement of different vaccine delivery systems for cancer therapy ⬇️

artículo científico publicado el 7 de enero de 2011

In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein

artículo científico publicado en 2014

In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

artículo científico publicado en 2015

In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications

artículo científico publicado en 2009

In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

artículo científico publicado en 2011

Innate immune system: Specific or non-specific?

artículo científico publicado en 2007

Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice

artículo científico publicado en 2007

Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients

artículo científico publicado en 2007

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model

artículo científico publicado en 2011

Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity

artículo científico publicado en 2010

Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against L. major-infected BALB/c mice

artículo científico publicado en 2017

Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model

artículo científico publicado en 2015

Leishmania-based expression systems.

artículo científico publicado en 2016

Leishmaniasis and various immunotherapeutic approaches.

artículo científico publicado en 2016

Leishmaniasis: Middle East and North Africa research and development priorities

artículo científico publicado en 2011

Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

artículo científico

Live vaccination tactics: possible approaches for controlling visceral leishmaniasis

artículo científico publicado en 2014

Mammalian host defense peptides and their implication on combating Leishmania infection

artículo científico publicado en 2016

Mini-chaperones: potential immuno-stimulators in vaccine design

artículo científico publicado en 2013

Old World cutaneous leishmaniasis challenges in Morocco, Algeria, Tunisia and Iran (MATI): a collaborative attempt to combat the disease

artículo científico publicado en 2017

PUF Proteins: Cellular Functions and Potential Applications.

artículo científico publicado en 2016

Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice.

artículo científico publicado en 2009

Post-Genomics and Vaccine Improvement for Leishmania

artículo científico publicado en 2016

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

artículo científico publicado en 2005

Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control

artículo científico publicado en 2018

Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy

artículo científico publicado en 2006

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

artículo científico publicado en 2005

Protein/Protein, DNA/DNA and DNA/Protein based vaccination strategies using truncated Omp2b against Brucella infection in BALB/c Mice.

artículo científico publicado en 2017

Recombinant Leishmania major lipophosphoglycan 3 activates human T-lymphocytes via TLR2-independent pathway

artículo científico publicado en 2015

Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.

artículo científico publicado en 2012

Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

artículo científico publicado en 2009

Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation

artículo científico publicado en 2002

Retracted: Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis

artículo científico publicado en 2015

Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae.

artículo científico publicado en 2009

Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model.

artículo científico publicado en 2016

T Helper 1 (Th1), Th2, and Th17 Responses to Leishmania major Lipophosphoglycan 3.

artículo científico publicado en 2016

Th1 cell development induced by cysteine proteinases A and B in localized cutaneous leishmaniasis due to Leishmania guyanensis

artículo científico publicado en 2003

The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women

article

The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen

artículo científico publicado en 2009

The outcome of arginase activity inhibition in BALB/c mice hosting Leishmania tropica

artículo científico publicado en 2020

The profile of cytokines and IgG subclasses in BALB/c mice after immunization with Brucella ribosomal gene

artículo científico publicado en 2008

The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis

artículo científico publicado en 1999

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin

artículo científico publicado en 2018

Transcriptomic profiling in Cutaneous Leishmaniasis patients

artículo científico publicado en 2020

Type I signal peptidase from Leishmania is a target of the immune response in human cutaneous and visceral leishmaniasis

artículo científico publicado en 2004

Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice.

artículo científico publicado en 2015

Lista de obras de Sima Rafati

A Synthetic Peptide 2Abz23S29 Reduces Bacterial Titer and Induces Pro-Inflammatory Cytokines in a Murine Model of Urinary Tract Infection

A non-pathogenic live vector as an efficient delivery system in vaccine design for the prevention of HPV16 E7-overexpressing cancers.

A novel non-invasive diagnostic sampling technique for cutaneous leishmaniasis

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis.

Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials

Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy

Arginase activity in pathogenic and non-pathogenic species of Leishmania parasites

Arginase activity of Leishmania isolated from patients with cutaneous leishmaniasis.

Building Research and Development Capacity for Neglected Tropical Diseases Impacting Leishmaniasis in the Middle East and North Africa: A Case Study.

C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice ⬇️

CD8(+) T cells in leishmania infections: friends or foes?

Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.

Chemokine-based immunotherapy: delivery systems and combination therapies.

Comparing acute and chronic human cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica focusing on arginase activity

Comparison of potential protection conferred by three immunization strategies (protein/protein, DNA/DNA, and DNA/protein) against Brucella infection using Omp2b in BALB/c Mice

Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice

Computational evaluation of modified peptides from human neutrophil peptide 1 (HNP-1)

Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice

Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection

Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals

DNA Integration in Leishmania Genome: An Application for Vaccine Development and Drug Screening

DNA plasmid coding for Phlebotomus sergenti salivary protein PsSP9, a member of the SP15 family of proteins, protects against Leishmania tropica

Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection

Delivery systems for Leishmania vaccine development

Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model

Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica.

EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice.

Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae

Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies

Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model

Enhanced protective efficacy of nonpathogenic recombinant leishmania tarentolae expressing cysteine proteinases combined with a sand fly salivary antigen

Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis

Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice

Expression of cysteine proteinase type I and II of Leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis

Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies

Generation of stable L. major(+EGFP-LUC) and simultaneous comparison between EGFP and luciferase sensitivity

Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice

Human neutrophil peptide-1 (HNP-1): a new anti-leishmanial drug candidate

Humoral and cellular immune responses against Type I cysteine proteinase of Leishmania infantum are higher in asymptomatic than symptomatic dogs selected from a naturally infected population

IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis

Identification of Leishmania major cysteine proteinases as targets of the immune response in humans

Identification of broadly conserved cross-species protective Leishmania antigen and its responding CD4+ T cells.

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine

Immunogenicity of a plant-derived edible chimeric EspA, Intimin and Tir of Escherichia coli O157:H7 in mice

Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.

Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.

Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen

Improvement of different vaccine delivery systems for cancer therapy ⬇️

In Vitro Evaluation of Influenza M2 and Leishmania major HSP70 (221-604) Chimer Protein

In Vitro Infectivity Assessment by Drug Susceptibility Comparison of Recombinant Leishmania major Expressing Enhanced Green Fluorescent Protein or EGFP-Luciferase Fused Genes with Wild-Type Parasite.

In silico analysis of chimeric espA, eae and tir fragments of Escherichia coli O157:H7 for oral immunogenic applications

In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

Innate immune system: Specific or non-specific?

Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice

Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model

Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity

Leishmania tarentolae expressing CXCL-10 as an efficient immunotherapy approach against L. major-infected BALB/c mice

Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model

Leishmania-based expression systems.

Leishmaniasis and various immunotherapeutic approaches.

Leishmaniasis: Middle East and North Africa research and development priorities

Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.

Live vaccination tactics: possible approaches for controlling visceral leishmaniasis

Mammalian host defense peptides and their implication on combating Leishmania infection

Mini-chaperones: potential immuno-stimulators in vaccine design

Old World cutaneous leishmaniasis challenges in Morocco, Algeria, Tunisia and Iran (MATI): a collaborative attempt to combat the disease

PUF Proteins: Cellular Functions and Potential Applications.

Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice.

Post-Genomics and Vaccine Improvement for Leishmania

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control